 |
市场调查报告书
商品编码
1608844
癫痫药物市场：依癫痫类型、药物、给药途径、年龄层、通路、地区Epilepsy Drugs Market, By Type of Epilepsy (Focal Epilepsy, Generalized Epilepsy, Reflex Epilepsy, and Others ), By Drugs, By Route of Administration (Oral, Injectable, and Others ), By Age Group, By Distribution Channel, By Geography |
||||||
癫痫药物市场预计到2024年将达到103.1亿美元，预计到2031年将达到147.7亿美元，2024年至2031年的复合年增长率为5.3%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2023年 | 2024年市场规模 | 103.1亿美元 |
| 实际资料 | 2019-2023 | 预测期 | 2024年至2031年 |
| 预测 2024-2031 年复合年增长率： | 5.30% | 2031 年金额预测 | 147.7亿美元 |
癫痫是一种慢性非传染性疾病，其特征是反覆发作。癫痫发作是一种短暂的不自主运动，涉及身体的一部分或整个身体。其症状包括脑部异常放电，导致癫痫发作。所有年龄层的人都可能受到影响，但在儿童和老年人中更为常见。虽然癫痫无法治疗方法，但约 70% 的癫痫病例可透过药物治疗控制。全球癫痫药物市场主要是由全球癫痫盛行率不断上升所推动的。正在开发的新药治疗方案的进步也支持了市场的成长。
市场动态
全球癫痫药物市场的成长主要是由全球癫痫盛行率不断上升所推动的。根据世界卫生组织 (WHO) 估计，到 2022 年，全球将有超过 5,000 万人受到癫痫的影响。市场也看到了各国医疗保健支出增加所带来的机会。然而，由于重磅药物的专利到期以及一些学名药面临的价格下降，市场成长可能会受到限制。此外，抗治疗性癫痫新药的市场开拓也是市场成长的机会。
本研究的主要特点
本报告对全球癫痫药物市场进行了详细分析，并列出了以2023年为基准年的预测期（2024-2031年）的市场规模和年复合成长率（CAGR%）。
它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
根据公司亮点、产品系列、主要亮点、绩效和策略等参数对全球癫痫药物市场的主要企业进行了分析。
调查涵盖的主要企业包括辉瑞、住友製药、诺华、雅培、葛兰素史克、梯瓦製药工业、赛诺菲、工业、Marinus Pharmaceuticals、Eisai、第一三共、Mylan NV、Dr. Reddy's Laboratories Ltd.、Sun Pharmaceutical Industries 、Neurelis, Inc.、Supernus Pharmaceuticals, Inc. 等。
从这份报告中获得的见解将帮助负责人和公司经营团队就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
全球癫痫药物市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进入者和财务分析师。
相关人员可以透过用于分析全球癫痫药物市场的各种策略矩阵来促进他们的决策。
目录
第一章 研究目的与前提
- 研究目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第三章市场动态、法规及趋势分析
- 市场动态
- 影响分析
- 主要亮点
- 监管场景
- 产品发布/核准
- PEST分析
- 波特分析
- 併购场景
- 流行病学
- 管道分析
第四章 癫痫药物市场，依癫痫类型，2019-2031
- 2024年及2031年市场占有率分析（%）
- 与前一年同期比较成长分析
- 细分市场趋势
- 局部癫痫
- 市场规模及预测、年成长与前一年同期比较
- 整体癫痫
- 市场规模及预测、年成长与前一年同期比较
- 反射性癫痫
- 市场规模及预测、年成长与前一年同期比较
- 其他（进行性性肌阵挛性癫痫等）
- 市场规模及预测、年成长与前一年同期比较
第五章 癫痫药物市场，依药物划分，2019-2031
- 第一代
- 第二代
- 第三代
第六章 癫痫药物市场，依给药途径，2019-2031
- 口服
- 可注射的
- 其他（鼻腔等）
第 7 章 癫痫药物市场，依年龄组，2019-2031
- 儿科的
- 成人
- 老年人
第8章癫痫药物市场，依分销管道，2019-2031
- 医院药房
- 零售药房
- 网路药房
第 9 章 癫痫药物市场，按地区，价值 2019-2031
- 北美洲
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
- 非洲
第10章竞争格局
- Pfizer Inc.
- Sumitomo Pharma Co., Ltd.
- Novartis AG
- Abbott
- GSK plc.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Takeda Pharmaceutical Company Limited
- Marinus Pharmaceuticals, Inc
- Eisai Co., Ltd
- DAIICHI SANKYO COMPANY, LIMITED
- Mylan NV
- Reddy's Laboratories Ltd
- Sun Pharmaceutical Industries Ltd.
- Neurelis, Inc.
- Supernus Pharmaceuticals, Inc.
第十一章分析师建议
- 命运之轮
- 分析师观点
- 一致的机会图
第十二章参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
The epilepsy drugs market is estimated to be valued at USD 10.31 Bn in 2024 and is expected to reach USD 14.77 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | 10.31 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 5.30% | 2031 Value Projection: | 14.77 Bn |
Epilepsy is a chronic non-communicable disease characterized by recurrent seizures, which are brief episodes of involuntary movement that may involve a part of the body or the entire body. Its symptoms include abnormal electrical discharges in the brain causing seizures. It affects people of all ages but is more common in children and older adults. There is no cure for epilepsy but seizures can be controlled in about 70% of cases with medication. The global epilepsy drugs market is primarily driven by the increasing prevalence of epilepsy worldwide. Advancements in the treatment options with new drugs in the pipeline also support the growth of this market.
Market Dynamics
Global epilepsy drugs market growth is primarily driven by increasing prevalence of epilepsy worldwide. In 2022, it was estimated that over 50 million people have epilepsy globally according to the World Health Organization. The market also witnesses opportunities due to the rising healthcare expenditures across various countries. However, the market growth can be restrained by the expiry of patents of blockbuster drugs and price erosion faced by some generic drugs. The development of novel drugs for treatment-resistant epilepsy also presents growth opportunities in the market.
Key Features of the Study:
This report provides in-depth analysis of the global epilepsy drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global epilepsy drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., Sumitomo Pharma Co., Ltd., Novartis AG, Abbott, GSK plc., Teva Pharmaceutical Industries Ltd., Sanofi, Takeda Pharmaceutical Company Limited, Marinus Pharmaceuticals, Inc, Eisai Co., Ltd, DAIICHI SANKYO COMPANY, LIMITED, Mylan N.V., Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Ltd., Neurelis, Inc., and Supernus Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global epilepsy drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epilepsy drugs market
Market Segmentation
- Type of Epilepsy Insights
- Focal Epilepsy
- Generalized Epilepsy
- Reflex Epilepsy
- Others (Progressive Myoclonic Epilepsy, etc.)
- Drugs Insights
- 1st Generation
- 2nd Generation
- 3rd Generation
- Route of Administration Insights
- Oral
- Injectable
- Others (Nasal, etc.)
- Age Group Insights
- Pediatric
- Adults
- Geriatric
- Distribution Channel Insights
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Sumitomo Pharma Co., Ltd.
- Novartis AG
- Abbott
- GSK plc.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Takeda Pharmaceutical Company Limited
- Marinus Pharmaceuticals, Inc
- Eisai Co., Ltd
- DAIICHI SANKYO COMPANY, LIMITED
- Mylan N.V.
- Reddy's Laboratories Ltd
- Sun Pharmaceutical Industries Ltd.
- Neurelis, Inc.
- Supernus Pharmaceuticals, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Epilepsy Drugs Market, By Type of Epilepsy
- Epilepsy Drugs Market, By Drugs
- Epilepsy Drugs Market, By Route of Administration
- Epilepsy Drugs Market, By Age Group
- Epilepsy Drugs Market, By Distribution Channel
- Epilepsy Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Epidemiology
- Pipeline Analysis
4. Epilepsy Drugs Market, Type of Epilepsy, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Focal Epilepsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Generalized Epilepsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Reflex Epilepsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others (Progressive Myoclonic Epilepsy, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
5. Epilepsy Drugs Market, By Drugs, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- 1st Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- 2nd Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- 3rd Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Epilepsy Drugs Market, By Route of Administration, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others (Nasal, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Epilepsy Drugs Market, By Age Group, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
8. Epilepsy Drugs Market, By Distribution Channel, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
9. Epilepsy Drugs Market, By Region, 2019 - 2031, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, Type of Epilepsy, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Drugs, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sumitomo Pharma Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbott
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GSK plc.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Takeda Pharmaceutical Company Limited
- Marinus Pharmaceuticals, Inc
- Eisai Co., Ltd
- DAIICHI SANKYO COMPANY, LIMITED
- Mylan N.V.
- Reddy's Laboratories Ltd
- Sun Pharmaceutical Industries Ltd.
- Neurelis, Inc.
- Supernus Pharmaceuticals, Inc.
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
儿科失神癫痫药物市场：按药物、疾病类型划分 - 全球预测 2025-2030
癫痫市场：KOL 洞察
癫痫药物市场：按产品类型、分销管道 - 全球预测 2025-2030
道斯症候群市场：依治疗类型、通路划分 - 全球预测 2025-2030 年
Gabapentin市场：依产品、给药途径、效力、应用、通路 - 2025-2030 年全球预测
亚太地区癫痫市场预测至 2030 年 - 区域分析 - 按类型、给药途径、治疗类型、年龄层和配销通路
北美癫痫市场预测至 2030 年 - 区域分析 - 按类型、给药途径、治疗类型、年龄层和配销通路
欧洲癫痫市场预测至 2030 年 - 区域分析 - 按类型、给药途径、治疗类型、年龄层和配销通路
远端癫痫市场、机会、成长动力、产业趋势分析与预测，2024-2032
全球加巴喷丁市场：依剂型、应用、给药途径、购买模式、分销管道和地区划分的机会和预测（2017-2031）